About 500 reports

Lung Cancer Surgery Market - Global Industry Analysis and Opportunity Assessment, 2019-2029 ##.

  • Cancer
  • Lung Cancer
  • Pathology
  • World
  • Market Size
  • COSTS OF FEW LUNG CANCER DRUGS ($)
  • FACTORS AFFECTING ADOPTION RATES OF LUNG CANCER THERAPEUTICS

Market Overview Strong prevalence of lung cancer Lung cancer is one of the most common cancer types.

  • Cancer
  • Lung Cancer
  • Therapy
  • World
  • Forecast

EXECUTIVE SUMMARY ##.

  • Cancer
  • Lung Cancer
  • Pathology
  • APAC
  • Market Shares

Company Overview Chapter ## Appendix: Acronyms List of Tables Summary Table : Global Market for Lung Cancer Therapeutics, by Type, Through 2023 Table ## : TNM Classification of Malignant Tumors of Lung Cancer Table ## : Five-Year Survival Rates, NSCLC and S

  • Cancer
  • Lung Cancer
  • Pathology
  • APAC
  • World

The 2021-2026 World Outlook for Lung Cancer Surgery ## INTRODUCTION ##. ## OVERVIEW ##. ## WHAT IS LATENT DEMAND AND THE P. I. E.?

  • Cancer
  • Lung Cancer
  • Pathology
  • World
  • Demand

GLOBAL LUNG CANCER THERAPEUTICS MARKET: ##IRESEARCH MARKET SHARE ANALYSIS List of Tables TABLE ##.

  • Cancer
  • Lung Cancer
  • United States
  • World
  • Market Size

GLOBAL LUNG CANCER DRUGS MARKET: ##IRESEARCH MARKET SHARE ANALYSIS List of Tables TABLE ##.

  • Cancer
  • Lung Cancer
  • United States
  • World
  • Market Size

The 2021-2026 World Outlook for Non-Small Cell Lung Cancer (NSCLC) Drugs ## INTRODUCTION ##. ## OVERVIEW ##. ## WHAT IS LATENT DEMAND AND THE P. I. E.?

  • Cancer
  • Lung Cancer
  • Pathology
  • World
  • Demand
  • AJCC Staging of Lung Cancer
  • presents an overview of the AJCC staging system for lung cancer.

Table ## presents a summary of definitions used in the AJCC Lung Cancer Staging System.

  • Immunotherapy
  • Lung Cancer
  • Therapy
  • United States
  • Merck & Co., Inc.

Non-Small Cell Lung Cancer (NSCLC) KOL Interview – UK This interview with a UK-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for non-small cell lung cancer (NSCLC).

  • Cancer
  • Lung Cancer
  • Pathology
  • United Kingdom
  • Market Size
  • RISING INCIDENCE OF LUNG CANCER
  • MARKET SIZE: GLOBAL LUNG CANCER LIQUID BIOPSY MARKET

Lung cancer liquid biopsy is one of the upcoming technologies in the in-vitro diagnostics market.

  • Laboratory
  • Lung Cancer
  • Biocept, Inc.
  • Exosome Diagnostics, Inc.
  • F. Hoffmann-La Roche Ltd.

BRAF Mutated Non-small Cell Lung Cancer (NSCLC) - Epidemiology Forecast to 2030 ##.

  • Cancer
  • Lung Cancer
  • France
  • United Kingdom
  • Forecast

Programmed death-ligand ## (PD-L##) Non-small Cell Lung Cancer (NSCLC) - Epidemiology Forecast to 2030 ##.

  • Lung Cancer
  • Germany
  • Japan
  • Spain
  • United States

Anaplastic lymphoma kinase Non Small Cell Lung Cancer (ALK-NSCLC) - Epidemiology Forecast to 2030 ##.

  • Lung Cancer
  • Germany
  • Japan
  • Spain
  • United States

Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC)— Epidemiology Forecast to 2030 ##.

  • Lung Cancer
  • Germany
  • Japan
  • Spain
  • United States

UNITED STATES LUNG CANCER THERAPEUTICS MARKET: ##IRESEARCH MARKET SHARE ANALYSIS List of Tables TABLE ##.

  • Cancer
  • Lung Cancer
  • Pathology
  • United States
  • Market Size

BRAF Mutated Non-small Cell Lung Cancer (NSCLC) -Market Insights, Epidemiology and Market Forecast—2030 ##.

  • Cancer
  • Lung Cancer
  • Pathology
  • United States
  • Forecast

Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC)-Market Insights, Epidemiology and Market Forecast to 2030 ##.

  • Cancer
  • Lung Cancer
  • Pathology
  • United States
  • Market Size

Small Cell Lung Cancer (SCLC)-Market Insights, Epidemiology and Market Forecast-2030 ##.

  • Cancer
  • Lung Cancer
  • Therapy
  • United States
  • Market Size

Non-Small Cell Lung Cancer (NSCLC) KOL Interview – US, East Coast This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for non-small cell lung cancer (NSCLC).

  • Cancer
  • Lung Cancer
  • Pathology
  • United States
  • Market Size

More than ##% of lung cancers are non-small cell lung cancer (NSCLC), with the exact proportion depending on the country in question.

  • Cancer
  • Lung Cancer
  • Pathology

Cellular-mesenchymal Epithelial Transition Factor (C-Met) Mutated Non-small Cell Lung Cancer (NSCLC)- Epidemiology Forecast to 2030 ##.

  • Lung Cancer
  • France
  • Germany
  • Japan
  • United Kingdom

UNITED STATES LUNG CANCER DRUGS MARKET: ##IRESEARCH MARKET SHARE ANALYSIS List of Tables TABLE ##.

  • Cancer
  • Lung Cancer
  • Pathology
  • United States
  • Forecast

Programmed death-ligand ## (PD-L##) Non-small Cell Lung Cancer (NSCLC)-Market Insights, Epidemiology and Market Forecast—2030 ##.

  • Cancer
  • Lung Cancer
  • Pathology
  • Therapy
  • United States

Risk Factors of Lung Cancer ##. ##. ##.

  • Cancer
  • Lung Cancer
  • Pathology
  • Therapy
  • United States

Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC)-Market Insights, Epidemiology and Market Forecast—2030 ##.

  • Cancer
  • Lung Cancer
  • Pathology
  • United States
  • Market Size

Lung Cancer Therapeutics Market: Global Industry Analysis, Trends, Market Size and Forecasts up to 2024 ##.

  • Cancer
  • Lung Cancer
  • Pathology
  • World
  • Market Size

Non-Small Cell Lung Cancer KOL Interview – NH, US Overview Datamonitor Healthcare interviewed a US-based oncologist with clinical trial and commercial experience of PD-##/ L## inhibitors to gauge his views on their current application within non-small cell lung

  • Cancer
  • Lung Cancer
  • Pathology
  • United States

The Latest in Immuno-Oncology: A Deep Dive into Non-Small Cell Lung Cancer (NSCLC) CONTENTS ## OVERVIEW ## ABOUT THE AUTHORS ## IMMUNO-ONCOLOGY OVERVIEW ## Immuno-oncology mechanisms and timelines ## PD-## and PD-L## inhibition ## CLINICAL TRIAL LANDSCAPE ## Active trials

  • Cancer
  • Lung Cancer
  • European Union
  • Japan
  • United States

Datamonitor Healthcare Non-Small Cell Lung Cancer KOL Interview – NY, US Overview Datamonitor Healthcare interviewed a US-based oncologist with clinical trial and commercial experience of PD-##/ L## inhibitors to gauge his views on their current application within non-sm

  • Cancer
  • Healthcare
  • Lung Cancer
  • Pathology
  • United States